5:45 PM
 | 
Jun 24, 2013
 |  BC Extra  |  Clinical News

Sanofi reports first Phase III data for new insulin glargine formulation

Sanofi (Euronext:SAN; NYSE:SNY) reported data from a pair of open-label Phase III trials evaluating once-daily subcutaneous U300 in over 1,600 Type II diabetics. In the EDITION I trial, U300 as an add-on to mealtime insulin led to...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >